Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice

2016 ◽  
Vol 15 (4) ◽  
pp. 381-388 ◽  
Author(s):  
Martin Wilhelm ◽  
Lothar Mueller ◽  
M. Craig Miller ◽  
Karin Link ◽  
Stefan Holdenrieder ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Metastatic Colorectal Cancer ◽  
Multicenter Study ◽  
Drug Monitoring ◽  
Routine Clinical Practice ◽  
Therapeutic Drug ◽  
Prospective Multicenter Study

Usefulness of Therapeutic Drug Monitoring of Antiretrovirals in Routine Clinical Practice

2004 ◽  
Vol 5 (4) ◽  
pp. 216-223 ◽  
Author(s):  
Michel Duong ◽  
Anne Golzi ◽  
Gilles Peytavin ◽  
Lionel Piroth ◽  
Marie Froidure ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Routine Clinical Practice ◽  
Therapeutic Drug

scholarly journals Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients

2021 ◽  
Vol 14 ◽  
pp. 175628482199990
Author(s):  
Sonia Facchin ◽  
Andrea Buda ◽  
Romilda Cardin ◽  
Nada Agbariah ◽  
Fabiana Zingone ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Point Of Care ◽  
Drug Clearance ◽  
Elisa Test ◽  
Enzyme Linked Immunosorbent Assay ◽  
Therapeutic Drug ◽  
Drug Concentrations ◽  
Inflammatory Bowel

Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditional immunoassay is not easily and rapidly accessible, making the translation of the results into treatment adjustment difficult. The availability of a point-of-care (POC) test for therapeutic drug monitoring (TDM) might represent an important step forward for improving the management of inflammatory bowel disease (IBD) patients in clinical practice. In this pilot study, we compared the results obtained with POC tests with those obtained by enzyme-linked immunosorbent assay (ELISA) in a group of IBD patients treated with Infliximab (IFX). We showed that POC test can reliably detect presence of antibody-to-IFX with 100% of specificity and 76% sensitivity, in strong agreement with the ELISA test ( k-coefficient = 0.84).

Sign in / Sign up

Export Citation Format

Share Document